These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 30279110

  • 1. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
    Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J.
    Clin Lung Cancer; 2019 Jan; 20(1):30-36.e3. PubMed ID: 30279110
    [Abstract] [Full Text] [Related]

  • 2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 3. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM.
    Lung Cancer; 2020 Feb; 140():35-41. PubMed ID: 31855703
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA.
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [Abstract] [Full Text] [Related]

  • 5. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.
    Ann Oncol; 2019 Feb 01; 30(2):290-296. PubMed ID: 30535340
    [Abstract] [Full Text] [Related]

  • 6. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
    Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S.
    Clin Lung Cancer; 2018 Jan 01; 19(1):65-73.e7. PubMed ID: 28780976
    [Abstract] [Full Text] [Related]

  • 7. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
    Nazha B, Zhuang TZ, Dada HI, Drusbosky LM, Brown JT, Ravindranathan D, Carthon BC, Kucuk O, Goldman J, Master VA, Bilen MA.
    Oncologist; 2022 Jun 08; 27(6):462-468. PubMed ID: 35462410
    [Abstract] [Full Text] [Related]

  • 8. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L, Liu H, Shao D, Liu Z, Wang J, Deng Q, Tang H, Yang H, Zhang Y, Qiu Y, Cui F, Tan M, Zhang P, Li Z, Liu J, Liang W, Wang Y, Peng Z, Wang J, Yang H, Mao M, Kristiansen K, Ye M, He J.
    Genes Chromosomes Cancer; 2018 Apr 08; 57(4):211-220. PubMed ID: 29277949
    [Abstract] [Full Text] [Related]

  • 9. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC, Loh CH, Toh GL, Lim CW, Chopra A, Chang AYC, Goh LL.
    Lung Cancer; 2018 Oct 08; 124():154-159. PubMed ID: 30268455
    [Abstract] [Full Text] [Related]

  • 10. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ, Zhang X, Patel PR, Shelton JW, Escott CE, Sica GL, Rossi MR, Hill CE, Steuer CE, Pillai RN, Ramalingam SS, Owonikoko TK, Behera M, Force SD, Fernandez FG, Curran WJ, Higgins KA.
    Cancer; 2017 Oct 01; 123(19):3681-3690. PubMed ID: 28608966
    [Abstract] [Full Text] [Related]

  • 11. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.
    Clin Lung Cancer; 2018 Sep 01; 19(5):e601-e608. PubMed ID: 29807856
    [Abstract] [Full Text] [Related]

  • 12. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
    Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Trejo Rosales R, Rojas L, Cruz-Rico G, Nagy R, Cabrera L, Vargas C, Saam J, Barrón F, Arrieta O.
    Oncology; 2021 Sep 01; 99(8):539-546. PubMed ID: 33902046
    [Abstract] [Full Text] [Related]

  • 13. Somatic mutations and immune checkpoint biomarkers.
    Parris BA, Shaw E, Pang B, Soong R, Fong K, Soo RA.
    Respirology; 2019 Mar 01; 24(3):215-226. PubMed ID: 30636374
    [Abstract] [Full Text] [Related]

  • 14. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A.
    Clin Cancer Res; 2018 Aug 01; 24(15):3528-3538. PubMed ID: 29776953
    [Abstract] [Full Text] [Related]

  • 15. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK, Kim KA, Lee CY, Kim S, Chang S, Cho BC, Shim HS.
    Clin Lung Cancer; 2019 Jan 01; 20(1):e123-e132. PubMed ID: 30391211
    [Abstract] [Full Text] [Related]

  • 16. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
    Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K.
    Cancer Sci; 2022 Jan 01; 113(1):221-228. PubMed ID: 34704312
    [Abstract] [Full Text] [Related]

  • 17. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    Laufer-Geva S, Rozenblum AB, Twito T, Grinberg R, Dvir A, Soussan-Gutman L, Ilouze M, Roisman LC, Dudnik E, Zer A, Rotem O, Lanman RB, Peled N.
    J Thorac Oncol; 2018 Nov 01; 13(11):1705-1716. PubMed ID: 30121392
    [Abstract] [Full Text] [Related]

  • 18. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.
    Clin Cancer Res; 2015 Aug 15; 21(16):3631-9. PubMed ID: 25567908
    [Abstract] [Full Text] [Related]

  • 19. Developing a New qPCR-Based System for Screening Mutation.
    Zhu J, Zhao Y, Liu M, Gonzalez-Rivas D, Xu X, Cai W, Qi H, Dai L, Wang Z, Song X, Jiang G, Yang Y.
    Small; 2019 Mar 15; 15(9):e1805285. PubMed ID: 30677225
    [Abstract] [Full Text] [Related]

  • 20. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.
    J Thorac Oncol; 2017 Feb 15; 12(2):258-268. PubMed ID: 27865871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.